RxDoctor Payments Data

Mary Angelopoulos, DO

Neurology · Northfield, ILNPI 1417069022

Payments from drug & device makers

$24,317in general payments, 2019–2025

Across 967 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • Novartis$2K
  • Livanova USA, Inc.$2K
  • AbbVie$2K
  • Biogen$1K
  • UCB, Inc.$1K
  • plus $13K from 49 others

What the payments were for

  • Consulting fees$1,8838%
  • Speaking & faculty fees$660%
  • Travel & lodging$9194%
  • Food & beverage$21,33988%
  • Education$1110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,317 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$96,132
Medicare patients
326
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe37$39,251
BriviactBrivaracetam24$38,024
Gabapentin221$2,862
Pregabalin26$2,773
Topiramate117$2,003
Duloxetine Hcl111$1,927
Carbidopa-LevodopaCarbidopa/Levodopa114$1,865
Oxcarbazepine33$1,774
Memantine Hcl69$1,521
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine56$1,349
Donepezil Hcl121$1,249
Levetiracetam67$1,195
Propranolol Hcl ErPropranolol Hcl30$1,171
Quetiapine Fumarate50$1,142
Nortriptyline Hcl76$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$1,429$38,02424 claims
Upsher-smith Laboratories LLCTopiramate$175$2,003117 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$11311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.

Other neurology in Northfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →